(Dis)solving the stroke problem by vWF inhibition?

Blood

Volumn 121, Issue 25, 2013, Pages 4972-4974

  Nieswandt, Bernhard ^a   Stoll, Guido ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CAPLACIZUMAB; GLYCOPROTEIN IB; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; FIBRINOLYTIC AGENT; NANOBODY;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EXPERIMENTAL MODEL; EXPERIMENTAL STROKE; HUMAN; MECHANICAL THROMBECTOMY; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS; ANIMAL; FIBRINOLYTIC THERAPY; MALE; METHODOLOGY; OCCLUSIVE CEREBROVASCULAR DISEASE;

ANIMALS; BRAIN INFARCTION; FIBRINOLYTIC AGENTS; INTRACRANIAL THROMBOSIS; MALE; SINGLE-DOMAIN ANTIBODIES; THROMBOLYTIC THERAPY;

EID: 84882313401     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-498725     Document Type: Note

References (10)

1. Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P. Reperfusion of cerebral artery thrombosis by the GPIb/vWF blockade with the nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013; 121(25):5088-5097.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-1757.
3. Chimowitz MI. Endovascular treatment for acute ischemic stroke—still unproven. N Engl J Med. 2013; 368(10):952-955.
4. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol. 2011; 589(Pt 17):4115-4123.
5. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115(17):2323-2330.
6. Adams HP Jr, Effron MB, Torner J, et al; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87-99.
7. Kellert L, Hametner C, Rohde S, Bendszus M, Hacke W, Ringleb P, Stampfl S. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke. 2013;44(5): 1453-1455.
8. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113(15):3600-3603.
9. Petri B, Broermann A, Li H, et al. von Willebrand factor promotes leukocyte extravasation. Blood. 2010; 116(22):4712-4719.
10. Zinkstok SM, Roos YB; ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380(9843):731-737.